Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection

J. Drew Payne, Kimberly Sims, Cynthia Peacock, Tanis Welch, Ruth E. Berggren

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Misinformation and promotion of well-intended but disproved therapies for COVID-19 have plagued evidence-based shared decision-making throughout the COVID-19 pandemic. In times of crisis, clinicians may feel that their strong inclination to prescribe potentially harmful, unproven therapies on behalf of their patients is supported by beneficence. Clinicians should mindfully identify and avoid commission bias during this pandemic, especially as more data have accumulated to assist with clinically sound decision-making. We describe a more evidence-based approach to treatment of early outpatient COVID-19, stressing the availability of Food and Drug Administration emergency use authorization therapies and considering plausibly beneficial, nonprescription supplements that are generally regarded as safe.

Original languageEnglish (US)
Pages (from-to)464-468
Number of pages5
JournalBaylor University Medical Center Proceedings
Issue number4
StatePublished - Jun 4 2021


  • COVID-19
  • SARS-CoV-2
  • colchicine
  • evidence-based
  • ivermectin
  • melatonin
  • outpatient therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection'. Together they form a unique fingerprint.

Cite this